Work

Significant Activity of the mTOR Inhibitor Sirolimus and HDAC Inhibitor Vorinostat in Heavily Pretreated Refractory Hodgkin Lymphoma Patients

Year: 2014

Type: article

Study design: Clinical Trial

Source: Klinische Pädiatrie

DOI: 10.1055/s-0034-1371153

Authors: F Janku, I Garrido-Laguna, V Velez-Bravo, G Falchook, V Subbiah, D Hong, Y Oki, J Westin, C Nunez, L Fayad, L Kwak, S Neelapu, E Shpall, J Wheler, W Lang, B Salhia, F Meric-Bernstam, R Kurzrock, M Fanale

Institutions: The University of Texas MD Anderson Cancer Center, Huntsman Cancer Institute, Translational Genomics Research Institute, Moores Cancer Center

Language: English

Topic: Lymphoma Diagnosis and Treatment

Subfield: Pathology and Forensic Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2327149494

FWCI:

Cites:

Cited by:

Related to: 10